Theratechnologies (THTX) announced that the United States FDA has assigned a Prescription Drug User Fee Act goal date of March 25, 2025 to the company’s recently submitted supplemental Biologics License Application for the F8 formulation of tesamorelin. If approved by the FDA, the F8 formulation is intended to replace the F4 formulation, which is sold in the U.S. under the trade name EGRIFTA SV. The new formulation is patent protected in the U.S. until 2033.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies announces preliminary tolerability, efficiacy data for TH1902
- Theratechnologies Shows Promise in Ovarian Cancer Trial
- Theratechnologies Secures Financing for Strategic Growth
- Theratechnologies Expands Portfolio with Ionis Deal
- Theratechnologies enters exclusive licensing agreement with Ionis